Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)

Trial Identifier: ACE-LY-111
Sponsor: AcertaPharma
Collaborator:
AstraZeneca
NCTID:: NCT03527147
Start Date: June 2018
Primary Completion Date: March 2021
Study Completion Date: March 2021
Condition: Non-Hodgkin's Lymphoma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version

Trial Locations

Country Location
GB London, GB, W1G 6AD
GB Oxford, GB, OX3 7EJ
US, CA Los Angeles, CA, US, 90095
US, FL Sarasota, FL, US, 34232
US, GA Atlanta, GA, US, 30322
US, LA New Orleans, LA, US, 70112
US, MD Bethesda, MD, US, 20892
US, NE Omaha, NE, US, 68198
US, NY Rochester, NY, US, 14642
US, TN Nashville, TN, US, 37203
US, VA Charlottesville, VA, US, 22908
US, WA Seattle, WA, US, 98104